MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s00415-023-11667-5

Медицинская библиотека · Journal of neurology · 2023

Dysautonomia associated with immune checkpoint inhibitors.

Tezuka Toshiki, Okuzumi Shinichi, Nakashima Chiho, Ide Toshihiro, Imai Shungo, Mitsuboshi Satoru, Kuwahara Yuki, Takizawa Tsubasa, Seki Morinobu, Minematsu Naoto, Aragane Naoko, Nakahara Jin, Hori Satoko, Nakane Shunya, Suzuki Shigeaki

ОбзорСтатьяПеревод в очереди

Аннотация

OBJECTIVE

The purpose of this study is to report the clinical characteristics of dysautonomia associated with immune checkpoint inhibitors (ICIs).

METHODS

We reported two patients with autoimmune autonomic ganglionopathy (AAG) occurring as immune-related adverse events (irAEs). We also performed a review of previous case reports presenting dysautonomia during ICI therapy. Moreover, we conducted pharmacovigilance analyses using the US Food and Drug Administration Adverse Events Reporting System (FAERS) to investigate dysautonomia associated with ICI.

RESULTS

Two patients in our care developed both AAG and autoimmune encephalitis following ICI therapy for lung cancers. We comprehensively reviewed 13 published cases (M:F = 11:2, mean onset age of 53 years) with ICI-associated dysautonomia including AAG (n = 3) and autonomic neuropathy (n = 10). Of these, ICI monotherapy was performed in seven and combination ICI use in six. In 6 of 13 patients, dysautonomia appeared within one month after the start of ICIs. Orthostatic hypotension was observed in 7 and urinary incontinence or retention in five. All patients except three showed gastrointestinal symptoms. Anti-ganglionic acetylcholine receptor antibodies were undetectable. All but two patients received immune-modulating therapy. Immuno-modulating therapy was effective in three patients with AAG and two patients with autonomic neuropathy, but ineffective in the others. Five patients died, of either the neurological irAE (n = 3) or cancer (n = 2). The pharmacovigilance analyses using FAERS showed that ipilimumab monotherapy and the combination of nivolumab and ipilimumab constituted significant risks for developing dysautonomia, consistent with the review of literature.

CONCLUSION

ICIs can cause dysautonomia including AAG, and autonomic neuropathy is a neurological irAE.

Для цитирования: Tezuka Toshiki, Okuzumi Shinichi, Nakashima Chiho, Ide Toshihiro, Imai Shungo, Mitsuboshi Satoru, Kuwahara Yuki, Takizawa Tsubasa, Seki Morinobu, Minematsu Naoto, Aragane Naoko, Nakahara Jin, Hori Satoko, Nakane Shunya, Suzuki Shigeaki. Dysautonomia associated with immune checkpoint inhibitors.. Journal of neurology. 2023. DOI: 10.1007/s00415-023-11667-5.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.